We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serum Test Detects Bacterial Infection in Autoimmune Diseases

By LabMedica International staff writers
Posted on 19 Jun 2012
Print article
The serum procalcitonin test (PCT) has been used to detect bacterial infection in patients with autoimmune diseases.

The clinical manifestations of disease flare and infection overlap and are identified by similar laboratory markers so there is an urgent need for a reliable biomarker that discriminates early infection from disease flare in febrile patients with autoimmune disease (AD).

Scientists from Chang Gung University (Tao Yuan, Taiwan) have reviewed studies carried out between January 1966 and October 2011 that had evaluated PCT as a diagnostic marker for bacterial infection in patients with AD, which included nine studies for PCT and five studies for C-reactive protein (CRP).

In healthy individuals, serum PCT is normally undetectable below 0.05 ng/mL, but the level increases rapidly after bacterial infection. In contrast to CRP, PCT does not rise with noninfectious inflammation or nonbacterial infections, making it a potentially useful marker to distinguish bacterial infection from disease flare in the setting of autoimmune disease.

The positive likelihood ratio for PCT was sufficiently high to be qualified as a rule-in diagnostic tool, while the negative likelihood ratio was not sufficiently low to be qualified as a reliable rule-out diagnostic tool. The area under the receiver-operating curve was higher for PCT than for CRP. Both markers had suboptimal negative likelihood ratios and so are not suitable tests for excluding bacterial infection in febrile patients with autoimmune diseases.

The authors conclude that different cut off levels are needed to optimize the discriminative capability of PCT for different autoimmune diseases. However, this requires a large study or studies of patients with the same autoimmune disease.

Until the results of such studies are available, they recommend using a standard PCT cut off value of 0.5 ng/mL, which has reasonable sensitivity of 76% and specificity of 88%.

Shy-Shin Chang, MD, lead author of the study said, "Analysis of the pooled data suggests that PCT is a more specific indicator of bacterial infection than CRP, but that CRP is a more sensitive indicator of bacterial infection than PCT." The study was published online on May 17, 2012, in the journal Arthritis and Rheumatism.

Related Links:
Chang Gung University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more